Skip to main content

Danaher Expects TripleTOF 5600 to Drive AB Sciex Revenue Growth for 2010

Premium

This story originally ran on July 22.

Danaher officials this week said the firm expects its AB Sciex division to see mid-single-digit revenue growth in 2010 based in part on sales of the company's new TripleTOF 5600 mass spectrometer.

AB Sciex introduced the instrument at the American Society for Mass Spectrometry conference in May and will begin shipments later this year (PM 5/28/2010).

In an conference call to discuss Danaher's H1 earnings, CEO Lawrence Culp said that the TripleTOF 5600 rollout is "an important launch for us."

He added that customer evaluations are currently underway, "and the feedback continues to be net positive."

Danaher's medical technologies business, which includes AB Sciex, recorded sales of $1.9 billion for H1 2010 – up 24 percent from $1.45 billion in H1 2009. The business posted an operating profit of $152 million, up 2 percent from $149 million in the year-ago period.

Culp cited costs related to the January acquisition of the AB Sciex joint venture from Life Technologies' Applied Biosystems unit and MDS.for a 240 basis point year-over-year decline in operating profit margins in the medical technologies division.

"[The integration of AB Sciex] is a fairly complicated decoupling from two parents. You've got IT systems that are being transitioned; you've got other one-time expenses like leases that are being broken to stitch this business together," he said.

In its earnings report the company noted that it "expects acquisition-related charges, primarily related to the AB Sciex and Molecular Devices acquisitions, to adversely impact the [medical technology] segment's operating profit margins through the balance of 2010, but at lower levels than experienced in the first half of 2010."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.